Dr. Ao Li received Ph.D. from Cancer Hospital and Institute, Chinese Academy of Medical Sciences, Beijing, China and has worked in the field of kidney disease for almost 10 years and published several papers in different journals as first author or co-responding author. She has strong background and expertise and experiences in am working on elucidating the molecular mechanisms and pathogenesis of Polycystic Kidney Disease (PKD) and has worked in Prof. Guanqing Wu’s Lab in Division of Translational Cancer Research and Therapy, State Key Laboratory of Molecular Oncology of Cancer Institute. Her research focused on the application of molecular technology and well-extended genetic knowledge to unravel the pathogenesis and molecular mechanism of human genetic-related diseases. She have strong background and experiences in elucidating the molecular mechanisms and pathogenesis of human genetic disease: autosomal dominant polycystic disease (ADPKD) and autosomal recessive polycystic disease (ARPKD).

Dedicated, strategic biopharmaceutical physician with 12 years of experience in industry and 14 years in
academic medicine completing both bench (CLCN5 gene, X-linked renal failure, renal stone) and clinical
research (Autosomal Polycystic Kidney Disease).
Extensive clinical experience as an internist, nephrologist and geriatrician. Prior to medical school, I was
a physician assistant on the ground floor in the development of the Division of Geriatrics and
Gerontology at UCLA, working with leaders in the field nationally. Completed medical school at the
University of Washington, an internship /residency in internal medicine at the Johns Hopkins Hospital,
and a joint clinical fellowship in Nephrology and Gerontology at the Harvard teaching hospitals followed
by a 5-year fellowship in the Department of Genetics at Harvard Medical School.